Aspect Biosystems

Aspect Biosystems is a pioneering biotechnology company focused on developing bioprinted tissue therapeutics to transform treatment options for some of the world’s most challenging diseases. Its full-stack tissue therapeutic platform integrates proprietary AI-powered bioprinting technology, computational design, therapeutic cells, and biomaterials to create next-generation cell therapies.

Aspect is advancing a therapeutic pipeline targeting a range of endocrine and metabolic diseases, including diabetes, obesity, rare endocrine disorders, and liver disease. Its strategy includes both internal R&D and strategic partnerships, such as a major collaboration with Novo Nordisk in diabetes and obesity.

‍